Active — Not RecruitingNot Applicable

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

South Korea100 participantsStarted 2018-07-01

Plain-language summary

Although immune checkpoint inhibitors including nivolumab and pembrolizumab are now available for the management of hepatobiliary cancers in Korea, there is a lack of data for the efficacy and safety of these agents in the real-world setting. This study aims to prospectively evaluate the efficacy of safety of nivolumab and pembrolizumab against advanced hepatocellular carcinoma and biliary tract cancer.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Biliary tract cancer (intrahepatic or extrahepatic cholangiocarcinoma and gallbladder cancer) or hepatocellular carcinoma * Planned immune checkpoint inhibitors including nivolumab or pembrolizumab * Written informed consent Exclusion Criteria: * Not available for the treatment with immune checkpoint inhibitors

What they're measuring

Objective response rate

Timeframe: 6 months

Trial details

NCT IDNCT03695952

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-07-30

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials